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ABSTRACT
Background. We performed this study to develop 
a new scoring system to stratify different levels of 
risk of developing new onset diabetes after trans-
plantation (NODAT) in patients who underwent renal 
transplantation. Many prognostic variables have been 
previously described but few efforts have been made 
to group them in order to enhance their individual 
predictive power.
Material and methods. In a first phase, 100 patients 
were prospectively analysed to determine which 
factors were significantly associated with the deve-
lopment of NODAT. A risk score ranging from 0 to 10 
points was developed using a multivariate analysis. 
In a second phase, such score was validated in a new 
sample of 100 patients.
Results. BMI ≥ 23.5 kg/m2, age ≥ 38.5 years, fasting 
blood sugar at 1st post-operative day ≥ 159.5 mg/dL, 
fasting blood sugar at 5th post-operative day ≥ 122.5 
mg/dL and HOMA-IR ≥ 2.5 were found as independent 
prognostic variables. A clear distinction was shown 
among categories of low, intermediate and high risk, 
defined according to the risk score.
Conclusion. This new scoring framework is basic and 
simple to accomplish. It permits a generally excellent 
stratification of risk of developing NODAT in patients 
undergoing renal transplantation. They might be 
separated in three risk stratification cohorts, which 
could be of help in early identification of NODAT. (Clin 
Diabetol 2020; 9)
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Introduction
New‑onset diabetes after transplantation (NODAT) 
refers to diabetes that occurs in previously non‑diabetic 
persons after solid‑organ transplantation, according to 
International consensus guidelines published in 2003 
[1, 2]. There are many risk factors of NODAT. Some 
risk factors are the same as in general risk factors for 
diabetes mellitus (DM), while some others are specific 
to transplantation. 
Some common risk factors include age, obesity, 
African‑American and Hispanic [3–6]. In addition, some 
risk factors are unique to the transplant population. 
These include specific agents used for immunosup‑
pression, human leukocyte antigen mismatch, donor 
sex and type of underlying renal disease [7]. Impaired 
glucose tolerance prior to transplant [8] and hypergly‑
caemia in the immediate perioperative period [9, 10] 
may identify patients at higher risk for the develop‑
ment of NODAT. There is paucity of data with regards 
to the development of risk scores for the development 
of new onset diabetes after transplantation (NODAT) 
from South‑East Asian population. Although data from 
western population are available, we intended to de‑
velop the same for our population which is place of resi‑
dence for almost one-fifth of the world’s population. 
Furthermore, the pre‑transplant and peri‑transplant 
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risk factors in our study population also differ con‑
siderably from the western population which calls for 
development of population specific predictive model 
for development of NODAT in the intended population. 
We conducted the present study to test the prognostic 
value of a combination of such risk factors resulting in 
a prospectively designed score that could be capable of 
making a clear distinction of different clinical outcomes 
with regards to development of NODAT applied to 
patients coming to hospital for renal transplantation. 
With that purpose we chose the most widely available 
prognostic variables that, in our model, provided the 
best independent information for the development of 
NODAT. The new score was applied in another cohort 
of patients consecutively admitted to renal transplant 
units who were not enrolled in trials of therapeutic 
interventions.
Material and methods
Study population
This was a single‑centred prospective study of 
200 subjects who underwent renal transplantation 
over a period of four years in a tertiary care centre in 
eastern India.
The inclusion criteria comprised of adult subjects 
with end stage renal disease who underwent live donor 
kidney transplantation and absence of diabetes prior 
to kidney transplantation, defined according to the 
American Diabetes Association (ADA) guideline. None 
of these patients were on any oral hypoglycaemic 
agents or insulin prior to kidney transplantation. All 
patients received their allograft from a living (related 
or unrelated) donor. All subjects received standard 
immunosuppressive medications that included triple 
immunosuppressive medications namely tacrolimus, 
mycophenolate mofetil or mycophenolate sodium 
and steroids with induction (ATG). Immunosuppres‑
sive therapy comprised tacrolimus (initiation dose of 
0.15 mg/kg) (with target blood level of tacrolimus 
10–15 ng/ml between 1st 3month, 5–10 ng/ml between 
3rd to 6th month and 3–5 ng/ml in 6th to 12th month), 
prednisolone (20 mg/d) (with gradual tapering of dose 
2.5 mg per month with target of 5 mg at the end of 
6th month), and or mycophenolate mofetil (1.5 g/d). 
Previous studies in NODAT have modified the immuno‑
suppressive regimen to prevent NODAT development. 
But ADA recommends that immunosuppressive regi‑
mens associated with best patient and graft survival 
should be used, irrespective of post‑transplantation 
diabetes mellitus risk [11]. Subjects who were capable 
of understanding the study and gave informed written 
consent for study participation were only included. 
Patients with a diagnosis of DM prior to kidney trans‑
plantation based on ADA criteria, for diagnosis of DM 
[12], or those receiving anti‑diabetic medications or 
those who were not capable of providing consent were 
excluded from the study. 
‘Prediabetes’ in our study was defined according to 
ADA 2016 guidelines as HbA1c value 5.7–6.4%. Those 
who are non‑diabetic and underwent renal transplan‑
tation are further evaluated for the development of 
NODAT during 1‑year post‑transplantation follow‑up. 
Post‑transplant follow‑up done on weekly basis for 1st 
month, every 15th day from 1st month to 3rd month, 
monthly from 3rd month to 12th month. Each transplant 
patient was followed up for 1‑year post‑transplant or 
for 6 months post‑development of NODAT, whichever 
is later. NODAT was defined according to standard 
ADA criteria provided the patient was receiving therapy 
(oral hypoglycaemic drugs or insulin) at 3 months post‑
transplant. Immediate posttransplant hyperglycaemia 
was defined as a random blood sugar (RBS) ≥ 200 mg/dL 
[1] or requirement of insulin on > 2 days whereas the 
patient was of dextrose-containing fluid infusions (usu‑
ally from the 4th postoperative day). 
In addition to routine transplant workup, pretrans‑
plant BMI, family history of DM, HbA1c, fasting insulin 
level, fasting C‑peptide level, serology for hepatitis B, C 
and serum magnesium level were evaluated in all patients 
2 days prior to transplant. Pre‑operative insulin resistance 
(HOMA‑IR), insulin sensitivity (HOMA‑S) beta‑cell function 
(HOMA‑B and C‑peptide levels) were assessed. All the 
above pre‑transplant variables were further compared 
between NODAT and non‑NODAT subjects at the end of 
the study to assess their strength of association.
Data management and statistical analysis
Descriptive statistics was analysed with SPSS ver‑
sion 17.0 software for windows. In order to develop a 
risk score, all demographic, clinical, and biochemical 
variables were routinely collected. Continuous vari‑
ables were presented as mean ± SD and analysed by 
unpaired t test. Categorical variables were expressed as 
frequencies and percentages. Nominal categorical data 
between the groups were compared using Chi‑square 
test or Fischer’s exact test as appropriate. A p value of 
< 0.05 was considered to be statistically significant. 
Univariate was analysis done to evaluate odds ratio of 
various parameters associated with increased risk of 
NODAT among study population.
Every variable resulting in a p value < 0.01 in the 
univariate model was entered into a multiple logistic 
regression analysis to determine which were indepen‑
dently related to the end‑points. 
The predictive accuracy of the multivariate model 
was evaluated using the C statistic, an index that 
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reflects the area under the receiver operating charac‑
teristic curve.
The odds ratio (OR) values obtained in the mul‑
tivariate analysis were used to develop the scoring 
system in the following way: if the OR was between 
1 and 1.9, one point was adjudicated; two points if it 
was between 2 and 2.9; three points between 3 and 
3.9 and four points if it exceeded the last value.
Once the risk score was developed, we conduc‑ 
ted a validation phase to assess its prognostic accu‑ 
racy in a prospectively collected new sample of 
patients.
The overall predictive ability of the risk score was 
then assessed with the C statistic and compared with 
that obtained from the multivariate model of the de‑
velopment phase.
Table 1. Baseline characteristics of the subjects who developed NODAT in development phase and validation phase
Development phase (n = 100) Validation phase (n = 100)
Age (years), mean (SD) 45.2 (10.93) 46 (11)
Family H/O diabetes mellitus, n (%) 25 (25) 32 (32)
BMI [kg/m2], mean (SD) 22.62 (4.03) 23.15 (5.77)
Hepatitis B infection, n (%) 3 (3) 3 (3)
Hepatitis C infection, n (%) 3 (3) 3 (3)
Autosomal dominant polycystic kidney disease, n (%) 4 (4) 3 (3)
Mean magnesium levels [mEq/L], mean (SD) 1.84 (0.51) 1.88 (0.37)
Mean total cholesterol levels [mg/dL], mean (SD) 139.41 (35.01) 136 (21)
Mean triglyceride levels [mg/dL], mean (SD) 84.02 (64.52) 89.5 (57.21)
Pre‑operative HbA1c > 5.7%, n (%) 14 (14) 16 (16)
Pre‑operative HbA1c (%), mean (SD) 5.34 (0.16) 5.12 (0.1)
ABO compatibility transplant, n (%) 94 (94) 96 (96)
HOMA‑IR, mean (SD) 1.87 (1.08) 1.84 (1.11)
HOMA‑S, mean (SD) 79.35 (48.07) 84.57 (40.18)
HOMA‑beta cell function, mean (SD) 64.14 (3.64) 68.23 (4.21)
C‑peptide level, mean (SD) 11.06 (5.09) 10.21 (6.21)
Table 2. The results of the univariate analysis
Variable OR 95% CI P value
Age (years), mean ± SD 1.084 1.033–1.138 0.004
Family H/O diabetes, n (%) 1.133 1.013–1.890 < 0.001
Fasting blood sugar‑day 1 [mg/dL] 2.032 1.412–3.785 < 0.001
BMI [kg/m2], mean ± SD 1.363 1.178–1.577 < 0.001
Hepatitis B infection, n (%) 7.4 0.638–85.81 0.28
Hepatitis C infection, n (%) 7.4 0.638–85.81 0.28
Fasting blood sugar‑day 5, mean ± SD 9.28 5.413–16.519 < 0.001
Autosomal dominant polycystic kidney disease 1.001 0.856–1.087 0.242
Mean magnesium level [mEq/L], mean ± SD 0.780 0.315–1.930 0.305
Mean total cholesterol level [mg/dL], mean ± SD 1.015 0.997–1.032 0.120
Mean triglycerides level [mg/dL], mean ± SD 1.008 0.998–1.018 0.066
Pre‑operative HbA1c (%) > 5.7% 2.315 1.389–2.561 < 0.001
Pre‑operative HbA1c (%), mean ± SD 1.057 1.029–1.185 0.001
ABO compatibility transplant 0.135 0.023–0.792 < 0.001
HOMA‑IR 0.987 0.932–0.998 0.001
HOMA‑S 0.957 0.921–0.997 < 0.001
HOMA‑beta cell function 0.956 0.901–0.978 0.001
C‑peptide level 1.987 1.057–2.184 < 0.001
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Results
Score development phase
One hundred patients were prospectively included 
in this phase. Among the 100 subjects included in 
the analysis, 24 patients (19 males and 5 females) 
developed NODAT during 1 year of follow‑up after 
transplantation.
Eighteen variables were included in the univari‑
ate analysis. We included the variables which had a p 
value less than 0.010 for multivariate analysis. Hence, 
we included 14 variables in the multiple regression 
model and only BMI, age, fasting blood sugar at 1st 
and 5th post‑operative day and HOMA‑IR were found 
as independent prognostic variables of NODAT. The C 
Figure 1. ROC of the significant predictor variables
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statistic for the multivariable model was 0.79 (95% CI 
0.74–0.89).
Development of scoring system
Therefore, according to the OR obtained, the scor‑
ing system was established as follows: 
 — age ≥ 38.5 years (OR = 1.231): 1 point;
 — BMI ≥ 23.5 kg/m2 (OR = 2.103): 2 points;
 — HOMA‑IR ≥ 2.5 (OR = 4.062): 4 points; 
 — FBS on 1st POD ≥ 159.5 (OR = 1.011): 1 point, and
 — FBS 5th day POD ≥ 122.5 (OR = 2.082): 2 points. 
As the highest possible score was 10 points, we 
divided it in tertiles so that we could assign each patient 
to one of three categories according to the score sum 
value: low‑risk when it was 0 to 2, intermediate‑risk 
when it was 3 to 6 and high‑risk when it was 7 to 10.
Validation phase
One hundred patients entered this phase of the 
study. Baseline characteristics were similar to the first 
except for a slightly higher prevalence of family history 
of diabetes in the validation cohort. The incidence of 
NODAT was similar in the development phase (24%) 
and validation phase (26%).
The incidence of NODAT occurred in 8.7% of low 
risk patients, 34.62% of intermediate risk and 46.43% 
of high risk patients (OR for high vs. low risk: 5.34, 95% 
CI 2.9–11.8, P < 0.001; OR for high vs. intermediate 
risk: 1.34, 95% CI 0.69–9.82, P = 0.044; OR for inter‑
mediate vs. low risk: 3.98, 95% CI 2.1–6.7, P = 0.001).
Predictive power of the score, as assessed by the 
C statistic was 0.78 (95% CI 0.67–0.88), similar to that 
found for the multivariate model.
Discussion
Although many demographic, clinical and bio‑
chemical markers have been clearly shown to correlate 
with development of NODAT, few efforts have been 
made to group them in order to improve their individual 
predictive power.
The scoring system proposed here is quite simple to 
implement and has a good ability to discriminate risk ac‑
cording to the C‑statistic value. All the information needed 
in our study to predict NODAT namely age, BMI, HOMA‑IR 
and FBS are easily available. All of these are non‑expensive 
and most importantly, they have a very good prognostic 
value. We divided the population studied into three groups: 
low, intermediate and high risk, which is a common practice 
among clinicians regarding many chronic diseases.
In the present study, age > 38.5 years was found 
to be a significant predictor for the development of NO‑
DAT. Increasing age is associated with increased risk for 
NODAT aspecially over the age of 40 years [6, 10, 12]. 
A study by Crosio et al. in 2078 patients showed that 
patients older than 45 years were 2.9 times increased 
risk of developing diabetes [13]. Every 10‑year increase 
in age leads to 1.5‑fold increased risk of diabetes [14].
In our study, pre‑transplant BMI > 23.5 kg/m2 is 
found to be significant prognostic variable for develop‑
ment of NODAT. Obesity independently correlates with 
the development of NODAT [3–5, 15, 16]. An analysis 
of 15,309 patients using the Organ Procurement and 
Transplant Network/United Network for Organ Sharing 
(OPTN/UNOS) database found that the risk of NODAT 
increased 1.4‑fold for those with a BMI of 25–30 and 
nearly doubled if the BMI was > 30 [17]. It remains 
unclear whether weight gain after transplantation is 
Table 4. Outcomes according to risk categorization in the validation phase
Low risk (n = 46) Intermediate risk (n = 26) High risk (n = 28)
Incidence of NODAT 4 (8.7) 9 (34.62) 13 (46.43)
OR for high vs. low risk 5.34, 95% CI 2.9–11.8
OR for high vs. intermediate risk 1.34, 95% CI 1.169–9.82
OR for intermediate vs. low risk 3.98, 95% CI 2.1–6.7
Table 3. Results of the multivariate analysis
B — coefficient C — statistics Best cut-off Sensitivity Specificity OR, 95% CI
Age 0.703 0.76 38.5 83.33 71.4 1.231 (1.133–1.938)
BMI 0.821 0.80 23.5 75.6 84.2 2.103 (1.278–2.878)
HOMA‑IR 1.439 0.81 2.5 74.2 78.8 4.062 (2.79–5.81)
FBS‑1st day POD 0.694 0.72 159.5 77.6 82.9 1.011 (1.002–1.018)
FBS‑5th POD 0.936 0.84 122.50 79 92.1 2.082 (1.037–4.088)
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the cause, however one study suggested pre‑transplant 
weight increases the risk for NODAT [18].
Midtvedt et al. using hyperinsulinaemia euglycemic 
clamps found insulin resistance as a common denomi‑
nator of KTRs with NODAT and IGT [19]. In study done 
by Bayes et al. NODAT patients showed significantly 
higher pre‑transplant plasma insulin concentrations 
and HOMA‑IR index compared to non‑NODAT patients 
[20]. We found HOMA‑IR of more than 2.5 had an OR 
of 4.062 for NODAT development. 
Patients with post‑transplant hyperglycemia in our 
study had a fourfold higher risk of developing NODAT. 
Similar results were seen in the study by Chakkera et al. 
in 200 posttransplant patients in Arizona [21]. A study 
from Chile reported 5.4‑fold higher risk of developing 
diabetes in patients with early hyperglycemia [22]. 
A French study found first post-transplantation capil‑
lary blood glucose and fasting blood glucose on 1st 
day tended to be higher in patients who developed 
diabetes 3 months later [23]. They reported maximum 
hyperglycaemia on the first post-operative day which 
decreased gradually during first 4 days of transplan‑
tation probably related to decrease in corticosteroid 
dosages and reduction in insulin resistance due to 
resolution of uraemia. A Belgian study demonstrated 
that a normal OGTT on the 5th post‑operative day was 
associated with a significantly decreased risk of NODAT 
at 3 months [24]. We also found that persistent post‑
operative day 5th FBS to have a higher odd of NODAT 
development compared to day 1 FBS. The significant 
risk of NODAT posed by posttransplant hyperglycaemia 
makes it prudent to follow up these patients more dili‑
gently and are likely to benefit from intensive glucose 
monitoring. Based on the available evidence, NODAT 
cannot be efficiently prevented by tailored immuno‑
suppression alone without compromising kidney graft 
survival. In the TIP‑study, early use of basal insulin in 
the immediate post‑transplantation period lower odds 
of NODAT by 73% throughout 1 year of follow‑up [25].
Only one previous study in predominantly white 
transplant recipients described a pretransplant predic‑
tive risk model for NODAT using seven pretransplant 
variables (age ≥ 50 years, planned use of maintenance 
corticosteroids; use of gout medicine; BMI ≥ 30 kg/m2; 
fasting glucose ≥ 100 mg/dL; fasting triglycerides 
≥ 200 mg/dL; and family history of type 2 diabetes) 
[26]. But they did not consider peri‑transplant risk 
factors like immediate post‑operative hyperglycemia 
which are strongly associated with NODAT. Moreover, 
there is variability in the use of gout medication and 
corticosteroids. In our study, be had a standard im‑
munosuppressive regimen for best transplant outcome 
in all patients and according to OR obtained, scoring 
system using five variables (age ≥ 38.5 years; BMI ≥ 
23.5 kg/m2; HOMA‑IR ≥ 2.5; FBS on 1st POD ≥ 159.5; 
FBS 5th day POD ≥ 122.5) was established. There is al‑
ways a concern of higher mortality in the person who 
develops NODAT which warrants adaptation of risk 
scores in routine clinical setting by transplant physi‑
cians. A study by Cooper et al. with 266 participants 
undergoing kidney transplantation found the age and 
sex adjusted mortality to be 1.69 times higher among 
patients with NODAT versus those without NODAT, 
hazard ratio 2.69 (95% CI 1.04–7.01) [27]. Cosio et al. 
described two fold increase in mortality with NODAT 
compared to nontransplant recipients, which was equal 
to that of pretransplant diabetes and independent of 
other factors known to reduce survival [28].
Conclusion
The morbidity and mortality associated with NO‑
DAT makes it prudent to a identify risk factors and 
develop a risk score for early detection of NODAT and 
stratify effective strategies for prevention and intensive 
treatment in resource‑limited setting wherein extensive 
monitoring in all patients is expensive. This new scoring 
framework is basic and simple to accomplish. It permits 
a generally excellent stratification of risk of developing 
NODAT in patients undergoing renal transplantation. 
They might be separated in three risk stratification 
cohorts, which could be of help in the decision‑making 
process. Our findings should be tested in a larger co‑
hort of patients in order to suggest clinical strategies 
based on them. If these data were confirmed, a highly 
aggressive approach as per recent evidences can be 
recommended in high risk and intermediate risk pa‑
tients and a more conservative one could be reserved 
for the low risk group.
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